Clinical Trials Logo

Filter by:
NCT ID: NCT03786640 Completed - Fatigue Clinical Trials

Abbott Brady 3T MRI PMCF

Start date: October 4, 2019
Phase:
Study type: Observational

The objective of this post-market, clinical follow up (PMCF) study, is to confirm the long-term safety of the Tendril STS and Isoflex leads, implanted with the Assurity MRI™ or Endurity MRI™ pacemakers, in patients undergoing a clinically indicated 3T MRI (3 Tesla Magnetic Resonance Imaging) scan.

NCT ID: NCT03785925 Completed - Neoplasm Metastasis Clinical Trials

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

PIVOT-10
Start date: April 29, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.

NCT ID: NCT03783000 Completed - Healthy Clinical Trials

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Start date: January 15, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this trial is to investigate the absolute oral bioavailability of BI 425809 administered as tablet (Test, T) compared to [C-14]-BI 425809 administered as intravenous microtracer (Reference, R).

NCT ID: NCT03782376 Completed - Crohn Disease Clinical Trials

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

POWER
Start date: December 20, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response (LoR) to subcutaneous (SC) every 8 Weeks (q8w) 90 mg ustekinumab maintenance therapy.

NCT ID: NCT03781999 Completed - Fitness Clinical Trials

The Effect of a Combination of Orange- and Pomegranate Actives on Physical Fitness in Elderly People

Start date: June 25, 2018
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the effect of daily supplementation of a combined orange- and pomegranate extract for a period of 4 weeks on physical fitness compared to placebo. In this crossover study, participants will daily receive either a placebo or Actiful®, a supplement containing 500 mg orange extract and 200 mg pomegranate actives, for 4 weeks followed by a wash-out period of 4 to 8 weeks. Subsequently, the second intervention period of 4 weeks (active product or placebo) will take place. The product and placebo will be supplied in capsules that participants can ingest with a glas of water (daily, prior to breakfast).

NCT ID: NCT03781414 Completed - Clinical trials for Liver Transplant Rejection

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

CONTRAIL I
Start date: October 7, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study was to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 dose regimens in liver transplant recipients.

NCT ID: NCT03781167 Completed - Clinical trials for Parkinson's Disease (PD)

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Start date: April 29, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.

NCT ID: NCT03780673 Completed - Liver Cirrhoses Clinical Trials

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

2018-001698-25
Start date: January 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF

NCT ID: NCT03779841 Completed - Clinical trials for Post-Operative Atrial Fibrillation

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.

NCT ID: NCT03779620 Completed - Clinical trials for Aortic Valve Stenosis

Valvosoft First-In-Man Study in Severe Symptomatic Aortic Stenosis

Start date: March 13, 2019
Phase: N/A
Study type: Interventional

This is a prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-man